GLCM Biosensor Test

SARS-CoV-2 virus test is the first vertical developed on the GLCM Biosensor Platform, which offers a non-invasive point-of-care, saliva-based diagnostic device which detects COVID-19 and all of its variants.

​

COVID-19 has been a life-changing event throughout the world, and the pandemic continues to be a major focus for governments, businesses, and industry as they adjust strategies to minimize the spread and resulting impacts on economies. Rapid and reliable testing, like GLCM’s Biosensor Test Platform, remains critical in mitigating COVID’s economic impacts.